

DAFTAR PUSTAKA

- Ansieau, S., Collin, G., & Hill, L. (2014). EMT or EMT-Promoting Transcription Factors, Where to Focus the Light? *Frontiers in Oncology*, 4(NOV), 353. <https://doi.org/10.3389/FONC.2014.00353>
- Chang, L., Zhou, G., Soufan, O., & Xia, J. (2020). miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. *Nucleic Acids Research*, 48(W1), W244–W251. <https://doi.org/10.1093/NAR/GKAA467>
- Chen, Y., Lun, A. T. L., & Smyth, G. K. (2016). From reads to genes to pathways: Differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. *F1000Research*, 5. <https://doi.org/10.12688/F1000RESEARCH.8987.2>
- Cheng, H., Chu, J., Yang, Y., Li, Y., Wang, M., Wu, H., Wang, M., Su, J., & Li, Q. (2024). Paris polyphylla saponins II inhibits invasive, migration and epithelial-mesenchymal transition of melanoma cells through activation of autophagy. *Toxicon*, 237, 107558. <https://doi.org/10.1016/J.TOXICON.2023.107558>
- Ciołczyk-Wierzbicka, D., & Laidler, P. (2018). The inhibition of invasion of human melanoma cells through N-cadherin knock-down. *Medical Oncology (Northwood, London, England)*, 35(4), 42. <https://doi.org/10.1007/S12032-018-1104-9>
- D'arcy, C., & Kiel, C. (2021). Cell adhesion molecules in normal skin and melanoma. *Biomolecules*, 11(8), 1213. <https://doi.org/10.3390/BIOM11081213/S1>

Davies, M. A. (2015). The multi-faceted roles of the PI3K-AKT pathway in melanoma.

Journal of Translational Medicine 2015 13:1, 13(1), K1-.

<https://doi.org/10.1186/1479-5876-13-S1-K1>

Dong, L., Tian, X., Zhao, Y., Tu, H., Wong, A., & Yang, Y. (2022). The Roles of

MiRNAs (MicroRNAs) in Melanoma Immunotherapy. *International Journal of*

Molecular Sciences, 23(23), 14775. <https://doi.org/10.3390/IJMS232314775>

Dzwierzynski, W. W. (2021). Melanoma Risk Factors and Prevention. *Clinics in Plastic*

Surgery, 48(4), 543–550. <https://doi.org/10.1016/j.cps.2021.05.001>

Fan, Y., & Xia, J. (2018). miRNet-Functional Analysis and Visual Exploration of

miRNA-Target Interactions in a Network Context. *Methods in Molecular Biology*

(Clifton, N.J.), 1819, 215–233. https://doi.org/10.1007/978-1-4939-8618-7_10

Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C. F., Ascierto, P. A., Croce, C. M.,

Mancini, R., Ciliberto, G., Fattore, L., Costantini, S., Malpicci, D., Ruggiero, C.

F., Ascierto, P. A., Croce, C. M., Mancini, R., & Ciliberto, G. (2017). MicroRNAs

in melanoma development and resistance to target therapy. *Oncotarget*, 8(13),

22262–22278. <https://doi.org/10.18632/ONCOTARGET.14763>

Flørenes, V. A., Øyjord, T., Holm, R., Skrede, M., Børresen, A. L., Nesland, J. M., &

Fodstad. (1994). TP53 allele loss, mutations and expression in malignant

melanoma. *British Journal of Cancer*, 69(2), 253.

<https://doi.org/10.1038/BJC.1994.48>

- Georgantas, R. W., Streicher, K., Luo, X., Greenlees, L., Zhu, W., Liu, Z., Brohawn, P., Morehouse, C., Higgs, B. W., Richman, L., Jallal, B., Yao, Y., & Ranade, K. (2014). MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D. *Pigment Cell & Melanoma Research*, 27(2), 275–286. <https://doi.org/10.1111/PCMR.12200>
- Ghafouri-Fard, S., Gholipour, M., & Taheri, M. (2021). MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets. *Frontiers in Oncology*, 11, 608987. <https://doi.org/10.3389/FONC.2021.608987>
- Grafanaki, K., Grammatikakis, I., Ghosh, A., Gopalan, V., Olgun, G., Liu, H., Kyriakopoulos, G. C., Skeparnias, I., Georgiou, S., Stathopoulos, C., Hannehalli, S., Merlino, G., Marie, K. L., & Day, C. P. (2023). Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response. *Pharmacology & Therapeutics*, 248. <https://doi.org/10.1016/J.PHARMTHERA.2023.108466>
- Guo, W., Wang, H., & Li, C. (2021). Signal pathways of melanoma and targeted therapy. *Signal Transduction and Targeted Therapy* 2021 6:1, 6(1), 424-. <https://doi.org/10.1038/s41392-021-00827-6>
- Halaban, R. (1999). Melanoma cell autonomous growth: the Rb/E2F pathway. *Cancer Metastasis Reviews*, 18(3), 333–343. <https://doi.org/10.1023/A:1006396104073>
- Hartl, D., Leboulleux, S., Hadoux, J., Berdelou, A., Breuskin, I., Guerlain, J., & Schlumberger, M. (2023). TNM Classification. *Surgery of the Thyroid and*

Parathyroid Glands, 440–446. <https://doi.org/10.1016/B978-0-323-66127-0.00047-8>

Hossain, S. M., & Eccles, M. R. (2023). Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. *International Journal of Molecular Sciences* 2023, Vol. 24, Page 1601, 24(2), 1601. <https://doi.org/10.3390/IJMS24021601>

Huang, Y., Hong, W., & Wei, X. (2022). The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. *Journal of Hematology & Oncology* 2022 15:1, 15(1), 1–27. <https://doi.org/10.1186/S13045-022-01347-8>

Ilmu, B., Kulit, K., & Kelamin, D. (n.d.). *TINJAUAN PUSTAKA Melanoma Maligna Sukmawati Tansil Tan, Isabella Puspa Dewi*. 42(12).

Inamdar, G. S., Madhunapantula, S. R. V., & Robertson, G. P. (2010). Targeting the MAPK Pathway in Melanoma: Why some approaches succeed and other fail. *Biochemical Pharmacology*, 80(5), 624. <https://doi.org/10.1016/J.BCP.2010.04.029>

Janka, E. A., Várvolgyi, T., Sipos, Z., Soós, A., Hegyi, P., Kiss, S., Dembrovszky, F., Csupor, D., Kéring, P., Pécsi, D., Solymár, M., & Emri, G. (2021). Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis. *Frontiers in Oncology*, 11, 772165. <https://doi.org/10.3389/FONC.2021.772165/FULL>

- Jiang, M., Zhang, K., Zhang, Z., Zeng, X., Huang, Z., Qin, P., Xie, Z., Cai, X., Ashrafizadeh, M., Tian, Y., & Wei, R. (2025). PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. *MedComm*, 6(8), e70295. <https://doi.org/10.1002/MCO2.70295>
- Katz, B., Reis, S. T., Viana, N. I., Morais, D. R., Moura, C. M., Dip, N., Silva, I. A., Iscaife, A., Srougi, M., & Leite, K. R. M. (2014). Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. *PLoS One*, 9(11). <https://doi.org/10.1371/JOURNAL.PONE.0113700>
- Keung, E. Z., & Gershenwald, J. E. (2018). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. *Expert Review of Anticancer Therapy*, 18(8), 775. <https://doi.org/10.1080/14737140.2018.1489246>
- Klicka, K., Grzywa, T. M., Mielniczuk, A., Klinke, A., & Włodarski, P. K. (2022). The role of miR-200 family in the regulation of hallmarks of cancer. *Frontiers in Oncology*, 12, 965231. <https://doi.org/10.3389/FONC.2022.965231/BIBTEX>
- Kwong, L. N., & Davies, M. A. (2013). Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 19(19), 10.1158/1078-0432.CCR-13-0142. <https://doi.org/10.1158/1078-0432.CCR-13-0142>

Lee, J. W., Guan, W., Han, S., Hong, D. K., Kim, L. S., & Kim, H. (2018). MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. *Cancer Science*, *109*(5), 1404–1413. <https://doi.org/10.1111/CAS.13588>

Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G., & Ferrao, P. T. (2015). Phenotype Switching in Melanoma: Implications for Progression and Therapy. *Frontiers in Oncology*, *5*(FEB), 31. <https://doi.org/10.3389/FONC.2015.00031>

Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023). Cutaneous melanoma. *Lancet (London, England)*, *402*(10400), 485–502. [https://doi.org/10.1016/S0140-6736\(23\)00821-8](https://doi.org/10.1016/S0140-6736(23)00821-8)

Ma, T., Zhao, Y., Wei, K., Yao, G., Pan, C., Liu, B., Xia, Y., He, Z., Qi, X., Li, Z., Wang, J., & Shao, Y. (2016). MicroRNA-124 Functions as a Tumor Suppressor by Regulating CDH2 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*, *38*(4), 1563–1574. <https://doi.org/10.1159/000443097>

Ma, X., Choudhury, S. N., Hua, X., Dai, Z., & Li, Y. (2013). Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. *Carcinogenesis*, *34*(6), 1216. <https://doi.org/10.1093/CARCIN/BGT044>

- Madhunapantula, S. R. V., Mosca, P. J., & Robertson, G. P. (2011). The Akt signaling pathway: An emerging therapeutic target in malignant melanoma. *Cancer Biology & Therapy*, 12(12), 1032. <https://doi.org/10.4161/CBT.12.12.18442>
- Melnik, B. C. (2015). MiR-21: an environmental driver of malignant melanoma? *Journal of Translational Medicine*, 13(1), 202. <https://doi.org/10.1186/S12967-015-0570-5>
- Nascentes Melo, L. M., Kumar, S., Riess, V., Szylo, K. J., Eisenburger, R., Schadendorf, D., Ubellacker, J. M., & Tasdogan, A. (2023). Advancements in melanoma cancer metastasis models. *Pigment Cell & Melanoma Research*, 36(2), 206–223. <https://doi.org/10.1111/PCMR.13078>
- O'Brien, J., Hayder, H., Zayed, Y., & Peng, C. (2018). Overview of microRNA biogenesis, mechanisms of actions, and circulation. *Frontiers in Endocrinology*, 9(AUG), 388354. <https://doi.org/10.3389/FENDO.2018.00402/BIBTEX>
- Pagliuca, C., Di Leo, L., & De Zio, D. (2022). New Insights into the Phenotype Switching of Melanoma. *Cancers*, 14(24), 6118. <https://doi.org/10.3390/CANCERS14246118>
- Pampena, R., Michelini, S., Lai, M., Chester, J., Pellacani, G., & Longo, C. (2021). New systemic therapies for cutaneous melanoma: why, who and what. *Italian Journal of Dermatology and Venereology*, 156(3), 344–355. <https://doi.org/10.23736/S2784-8671.21.06936-4>

- Pearlman, R. L., Montes de Oca, M. K., Pal, H. C., & Afaq, F. (2017). Potential Therapeutic Targets of Epithelial-Mesenchymal Transition in Melanoma. *Cancer Letters*, 391, 125. <https://doi.org/10.1016/J.CANLET.2017.01.029>
- Pedri, D., Karras, P., Landeloos, E., Marine, J. C., & Rambow, F. (2022). Epithelial-to-mesenchymal-like transition events in melanoma. *The FEBS Journal*, 289(5), 1352–1368. <https://doi.org/10.1111/FEBS.16021>
- Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. *Signal Transduction and Targeted Therapy* 2016 1:1, 1(1), 1–9. <https://doi.org/10.1038/sigtrans.2015.4>
- Poniewierska-Baran, A., Śluczankowska-Głabowska, S., Małkowska, P., Sierawska, O., Zadroga, Ł., Pawlik, A., & Niedźwiedzka-Rystwej, P. (2022). Role of miRNA in Melanoma Development and Progression. *International Journal of Molecular Sciences* 2023, Vol. 24, Page 201, 24(1), 201. <https://doi.org/10.3390/IJMS24010201>
- Roi, A., Boia, S., Rusu, L. C., Roi, C. I., Boia, E. R., & Riviş, M. (2023). Circulating miRNA as a Biomarker in Oral Cancer Liquid Biopsy. *Biomedicines*, 11(3), 965. <https://doi.org/10.3390/BIOMEDICINES11030965>
- Rossi, M., Pellegrini, C., Cardelli, L., Ciciarelli, V., Nardo, L. Di, & Fagnoli, M. C. (2019). Familial Melanoma: Diagnostic and Management Implications.

Dermatology Practical & Conceptual, 9(1), 10.

<https://doi.org/10.5826/DPC.0901A03>

Rowling, E. J., Miskolczi, Z., Nagaraju, R., Wilcock, D. J., Wang, P., Telfer, B., Li, Y., Lasheras-Otero, I., Redondo-Muñoz, M., Sharrocks, A. D., Arozarena, I., & Wellbrock, C. (2020). Cooperative behaviour and phenotype plasticity evolve during melanoma progression. *Pigment Cell & Melanoma Research*, 33(5), 695. <https://doi.org/10.1111/PCMR.12873>

Sahranavardfard, P., Madjd, Z., Razavi, A. E., Ghanadan, A., Firouzi, J., Khosravani, P., Ghavami, S., Ebrahimie, E., & Ebrahimi, M. (2021). An Integrative Analysis of The Micro-RNAs Contributing in Stemness, Metastasis and B-Raf Pathways in Malignant Melanoma and Melanoma Stem Cell. *Cell Journal*, 23(3), 261–272. <https://doi.org/10.22074/CELLJ.2021.7311>

Sari, N. L. P. E. K., Saamia, V., Novitasari, N., & Kurniati, M. (2023). APLIKASI miRNA SEBAGAI BIOMARKER IDENTIFIKASI PADA INVESTIGASI FORENSIK. *Jurnal Ilmu Kedokteran Dan Kesehatan*, 9(4), 1225–1242. <https://doi.org/10.33024/JIKK.V9I4.8697>

Schuster, S. L., & Hsieh, A. C. (2019). The untranslated regions of mRNAs in cancer. *Trends in Cancer*, 5(4), 245. <https://doi.org/10.1016/J.TRECAN.2019.02.011>

Sethi, S., Ali, S., Sethi, S., & Sarkar, F. H. (2014). MicroRNAs in personalized cancer therapy. *Clinical Genetics*, 86(1), 68–73. <https://doi.org/10.1111/CGE.12362>

Sundararajan, S., Thida, A. M., Yadlapati, S., Mukkamalla, S. K. R., & Koya, S. (2024).

Metastatic Melanoma. *StatPearls*.

<https://www.ncbi.nlm.nih.gov/books/NBK470358/>

The Cancer Genome Atlas Program (TCGA) - NCI. (n.d.). Retrieved February 21,

2025, from <https://www.cancer.gov/ccg/research/genome-sequencing/tcga>

Toussi, A., Mans, N., Welborn, J., & Kiuru, M. (2020). Germline mutations

predisposing to melanoma. *Journal of Cutaneous Pathology*, 47(7), 606.

<https://doi.org/10.1111/CUP.13689>

Vandamme, N., & Berx, G. (2019). From neural crest cells to melanocytes: cellular

plasticity during development and beyond. *Cellular and Molecular Life Sciences:*

CMLS, 76(10), 1919. <https://doi.org/10.1007/S00018-019-03049-W>

Xing, Y., Ruan, G., Ni, H., Qin, H., Chen, S., Gu, X., Shang, J., Zhou, Y., Tao, X., &

Zheng, L. (2021). Tumor Immune Microenvironment and Its Related miRNAs in

Tumor Progression. *Frontiers in Immunology*, 12, 624725.

<https://doi.org/10.3389/FIMMU.2021.624725/BIBTEX>

Yamazaki, H., Chijiwa, T., Inoue, Y., Abe, Y., Suemizu, H., Kawai, K., Wakui, M.,

Furukawa, D., Mukai, M., Kuwao, S., Saegusa, M., & Nakamura, M. (2012).

Overexpression of the miR-34 family suppresses invasive growth of malignant

melanoma with the wild-type p53 gene. *Experimental and Therapeutic Medicine*,

3(5), 793–796. <https://doi.org/10.3892/ETM.2012.497/HTML>

- Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., Dedhar, S., Derynck, R., Ford, H. L., Fuxe, J., García de Herreros, A., Goodall, G. J., Hadjantonakis, A. K., Huang, R. J. Y., Kalcheim, C., ... Sheng, G. (2020). Guidelines and definitions for research on epithelial–mesenchymal transition. *Nature Reviews Molecular Cell Biology* 2020 21:6, 21(6), 341–352. <https://doi.org/10.1038/s41580-020-0237-9>
- Yeung, K. T., & Yang, J. (2016). Epithelial–mesenchymal transition in tumor metastasis. *Molecular Oncology*, 11(1), 28. <https://doi.org/10.1002/1878-0261.12017>
- Zarrilli, G., Galuppini, F., Angerilli, V., Munari, G., Sabbadin, M., Lazzarin, V., Nicolè, L., Biancotti, R., & Fassin, M. (2021). miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma. *International Journal of Molecular Sciences*, 22(7), 3640. <https://doi.org/10.3390/IJMS22073640>
- Zhang, W. C., Skiados, N., Aftab, F., Moreno, C., Silva, L., Corbilla, P. J. A., Asara, J. M., Hata, A. N., & Slack, F. J. (2022). MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state. *Cancer Gene Therapy* 2022 29:12, 29(12), 1878–1894. <https://doi.org/10.1038/s41417-022-00504-y>

Zhang, X., Wang, W., Wang, Y., & Jiang, G. (2021). Identification of genes and pathways leading to metastasis and poor prognosis in melanoma. *Aging (Albany NY)*, 13(18), 22474. <https://doi.org/10.18632/AGING.203554>